DPP4 and Cholecystitis: A meta-analysis and systematic review encompassing 82 randomized controlled trials revealed a significant association between DPP-4 inhibitors and an increased risk of cholecystitis, while no such association was found with an increased risk of cholecystolithiasis or other biliary diseases (He et al., 2022a).